Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bio-Rad Laboratories Inc. (BIO:NYSE), powered by AI.
Bio-Rad Laboratories Inc. is currently trading at $285.94. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bio-Rad Laboratories Inc. on Alpha Lenz.
Bio-Rad Laboratories Inc.'s P/E ratio is 10.3.
“Bio-Rad Laboratories Inc. trades at a P/E of 10.3 (undervalued) with solid ROE of 10.8%.”
Ask for details →Bio-Rad Laboratories Inc. operates as a leading manufacturer and distributor of life science research products and clinical diagnostics systems. Established in 1952 and headquartered in Hercules, California, the company plays a pivotal role in the healthcare and medical research sectors. Bio-Rad provides a broad range of products for life science research, including reagents, instruments, and software used for techniques such as gel electrophoresis, chromatography, and polymerase chain reaction (PCR). These tools facilitate advancements in biology and medical research, aiding in the discovery of genetic information and the analysis of cell functions. In the clinical diagnostics realm, Bio-Rad offers solutions used to identify, track, and diagnose diseases through blood and tissue analysis, impacting critical areas like diabetes testing, blood typing, and autoimmune disease testing. With a comprehensive portfolio that supports innovation and efficiency in research laboratories and hospitals, Bio-Rad Laboratories Inc. significantly contributes to the improvement of diagnostic procedures and research methodologies, cementing its role as a key player in the enhancement of global health and medical science.
“Bio-Rad Laboratories Inc. trades at a P/E of 10.3 (undervalued) with solid ROE of 10.8%.”
Ask for details →Bio-Rad Laboratories Inc. (ticker: BIO) is a company listed on NYSE in the Healthcare sector (Medical Devices). It has approximately 7,700 employees. Market cap is $7.8B.
The current price is $285.94 with a P/E ratio of 10.26x and P/B of 1.05x.
ROE is 10.84% and operating margin is 8.46%. Annual revenue is $2.6B.